These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 18183487)

  • 1. Modeling recombinant immunotoxin efficacies in solid tumors.
    Chen KC; Kim J; Li X; Lee B
    Ann Biomed Eng; 2008 Mar; 36(3):486-512. PubMed ID: 18183487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids.
    Wenning LA; Murphy RM
    Biotechnol Bioeng; 1999 Mar; 62(5):562-75. PubMed ID: 10099565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment.
    Reiter Y; Pai LH; Brinkmann U; Wang QC; Pastan I
    Cancer Res; 1994 May; 54(10):2714-8. PubMed ID: 8168102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity of intraperitoneal immunotoxins in a nude mouse model of human malignant mesothelioma.
    Griffin TW; Richardson C; Houston LL; LePage D; Bogden A; Raso V
    Cancer Res; 1987 Aug; 47(16):4266-70. PubMed ID: 3496960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.
    Bang S; Nagata S; Onda M; Kreitman RJ; Pastan I
    Clin Cancer Res; 2005 Feb; 11(4):1545-50. PubMed ID: 15746059
    [TBL] [Abstract][Full Text] [Related]  

  • 6. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
    Mazor Y; Noy R; Wels WS; Benhar I
    Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2.
    Xu F; Leadon SA; Yu Y; Boyer CM; O'Briant K; Ward K; McWatters A; Zhao X; Bae DS; DeSombre K; Zalutsky MR; Bast RC
    Clin Cancer Res; 2000 Aug; 6(8):3334-41. PubMed ID: 10955821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model.
    Poleszczuk J; Bodnar M; Foryś U
    Math Biosci Eng; 2011 Apr; 8(2):591-603. PubMed ID: 21631148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model.
    Weil-Hillman G; Runge W; Jansen FK; Vallera DA
    Cancer Res; 1985 Mar; 45(3):1328-36. PubMed ID: 3971376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T; Raso V
    Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Robustness of optimal controls for a class of mathematical models for tumor anti-angiogenesis.
    Schättler H; Ledzewicz U; Cardwell B
    Math Biosci Eng; 2011 Apr; 8(2):355-69. PubMed ID: 21631134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
    Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
    Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic analysis of immunotoxin uptake in solid tumors: role of plasma kinetics, capillary permeability, and binding.
    Sung C; Youle RJ; Dedrick RL
    Cancer Res; 1990 Nov; 50(22):7382-92. PubMed ID: 2224866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimal and suboptimal protocols for a mathematical model for tumor anti-angiogenesis in combination with chemotherapy.
    Ledzewicz U; Maurer H; Schättler H
    Math Biosci Eng; 2011 Apr; 8(2):307-23. PubMed ID: 21631132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective cytotoxicity to HER2-positive tumor cells by a recombinant e23sFv-TD-tBID protein containing a furin cleavage sequence.
    Wang F; Ren J; Qiu XC; Wang LF; Zhu Q; Zhang YQ; Huan Y; Meng YL; Yao LB; Chen SY; Xu YM; Yang AG
    Clin Cancer Res; 2010 Apr; 16(8):2284-94. PubMed ID: 20371697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of recombinant immunotoxins against LeY antigen expressing tumor cells: influence of affinity, size, and stability.
    Bera TK; Pastan I
    Bioconjug Chem; 1998; 9(6):736-43. PubMed ID: 9815167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antitumor effect of recombinant immunotoxin EGF-TCS in nude mice bearing human hepatocellular carcinoma].
    Yang HW; Yang HW; Li YM
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Oct; 27(10):1535-6. PubMed ID: 17959515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody engineering of recombinant Fv immunotoxins for improved targeting of cancer: disulfide-stabilized Fv immunotoxins.
    Reiter Y; Pastan I
    Clin Cancer Res; 1996 Feb; 2(2):245-52. PubMed ID: 9816166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor activity of SS(dsFv)PE38 and SS1(dsFv)PE38, recombinant antimesothelin immunotoxins against human gynecologic cancers grown in organotypic culture in vitro.
    Hassan R; Lerner MR; Benbrook D; Lightfoot SA; Brackett DJ; Wang QC; Pastan I
    Clin Cancer Res; 2002 Nov; 8(11):3520-6. PubMed ID: 12429643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
    Brinkmann U
    In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.